Mendus hosted a key opinion leader (KOL) webinar highlighting the current state of maintenance treatment and immunotherapy in acute myeloid leukemia (AML) patients. The event featured two leading clinical experts, Assoc. Prof. Dr. Amer Zeidan, MBBS, MHS, from the Yale School of Medicine, and Prof. Dr. med. Uwe Platzbecker, from the Leipzig University Hospital.
The discussion also sets the stage for the upcoming data that will be presented in an oral presentation at the American Society of Hematology Annual Meeting on December 12, 2022 from the ongoing Phase 2 ADVANCE II study evaluating DCP-001 as a potential maintenance therapy for AML patients in remission with measurable residual disease (MRD). The results will include the most recent survival data from the study, as well as extensive immunomonitoring data.
To watch the replay of the KOL event, please click here.
To register for the ASH 2022 Results webcast, please click here.